In vitro: EGF (25 ng/mL) or PMA (10 ng/mL) treated NCI-H292 cells (the human pulmonary mucoepidermoid carcinoma cell line). This evidence concerns the gene EGF and pulmonary mucoepidermoid carcinoma.